Moderna acquired Japan's OriCiro to strengthen mRNA R&D technology.

(Reuters)

[Financial Channel/Comprehensive Report] U.S. drugmaker Moderna (Moderna) agreed on Wednesday (4th) to acquire OriCiro Genomics, a Japanese bio-innovative therapy research and development company, for US$85 million (approximately NT$2.6 billion) to enhance its mRNA Research and development technology.

OriCiro is working on the development and commercialization of a cell-free synthesis and amplification of a DNA molecule that makes mRNA.

OriCiro said its technology will be combined with Moderna's treatments and vaccines.

Moderna's mRNA technology has been used to develop a Wuhan pneumonia vaccine.

Please read on...

Moderna's experimental cancer vaccine, based on the technology, was shown to fight melanoma, a type of skin cancer.

Grasp the pulse of the economy with one hand I subscribe to Free Finance Youtube channel

Already added friends, thank you

Welcome to 【Free Finance】

feel good

Already liked it, thank you.

related news